Evidence map›Paper›PMID 32792013›Full record

ArticleBMC biology2020

Reengineering anthrax toxin protective antigen for improved receptor-specific protein delivery.

Lukas Becker, Wouter P R Verdurmen, Andreas Plückthun

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. New Insights into LINC00346 and its Role in Disease.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Lukas BeckerDepartment of Biochemistry, University of Zurich, Winterthurerstr. 190, 8057, Zurich, Switzerland.
Wouter P R VerdurmenDepartment of Biochemistry, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, The Netherlands.
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Winterthurerstr. 190, 8057, Zurich, Switzerland. plueckthun@bioc.uzh.ch.ORCID 0000-0003-4191-5306
Radboud University Nijmegen · NLUniversity of Zurich · CHZHAW Zurich University of Applied Sciences · CH

Funding

Krebsliga Schweiz KFS-4147-02-2017Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030B_166676
6 · The paper itself

Abstract

backgroundTo increase the size of the druggable proteome, it would be highly desirable to devise efficient methods to translocate designed binding proteins to the cytosol, as they could specifically target flat and hydrophobic protein-protein interfaces. If this could be done in a manner dependent on a cell surface receptor, two layers of specificity would be obtained: one for the cell type and the other for the cytosolic target. Bacterial protein toxins have naturally evolved such systems. Anthrax toxin consists of a pore-forming translocation unit (protective antigen (PA)) and a separate protein payload. When engineering PA to ablate binding to its own receptor and instead binding to a receptor of choice, by fusing a designed ankyrin repeat protein (DARPin), uptake in new cell types can be achieved.

resultsPrepore-to-pore conversion of redirected PA already occurs at the cell surface, limiting the amount of PA that can be administered and thus limiting the amount of delivered payload. We hypothesized that the reason is a lack of a stabilizing interaction with wild-type PA receptor. We have now reengineered PA to incorporate the binding domain of the anthrax receptor CMG2, followed by a DARPin, binding to the receptor of choice. This construct is indeed stabilized, undergoes prepore-to-pore conversion only in late endosomes, can be administered to much higher concentrations without showing toxicity, and consequently delivers much higher amounts of payload to the cytosol.

conclusionWe believe that this reengineered system is an important step forward to addressing efficient cell-specific delivery of proteins to the cytosol.

Indexed as

Antigens, BacterialBacterial ToxinsGenetic EngineeringProtein BindingReceptors, Cell SurfaceReceptors, Peptideanthrax toxinAntigens, BacterialAntxr2 protein, mouseBacterial ToxinsReceptors, Cell SurfaceReceptors, PeptideAnthrax toxinCytosolic protein deliveryDARPinProtective antigen

Identifiers

PMID32792013
PMCPMC7427085
OpenAlexW3048998868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.